Real World Evidence
Meet your clinical, economic, and regulatory needs throughout a product's lifecycle using U.S. real world solutions.
-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Life Sciences
-
Healthcare
Life Sciences
Bringing together unparalleled healthcare data, advanced analytics, innovative technologies, and healthcare expertise to create intelligent connections that speed the development and commercialization of innovative medicines to improve patient lives.
Learn MoreLife Sciences
Healthcare
Accelerate digital innovation to enable smarter decisions that reduce cost, modernize patient and consumer engagement, and improve health outcomes.
Learn MoreHealthcare
U.S. PROGRESS POINT
A curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.
LEARN MOREU.S. BLOGS
Get the latest insights on our life sciences, healthcare, and medical technology solutions in the United States. Follow our blog today!
LEARN MORE
Launch Excellence, the U.S. Edition: The Rewrite of the Business of Launch – Optimize
"Aligning legislative requirements, payer expectations regarding pricing and evidence, and meeting patients’ needs is now crucial for successful launches.
Learn moreFact Sheet
Unlocking Success in Drug Development with External Comparators
IQVIA’s expert guidance and advanced methodologies can enhance the design of external comparators for regulatory decisions
May 27, 2024
The use of external comparators (ECs) in drug development is on the rise, fueled by real-world data (RWD) and advancements in personalized medicine. Notably, the period from 2015 to 2019 saw a 22% increase in RWD-based EC usage. This upward trend is expected to continue, especially following the FDA’s February 2023 draft guidance, which advocates for a nuanced, case-by-case assessment of EC cohort designs.
While EC studies can significantly augment product lifecycles, from streamlining clinical trial design to strengthening real-world evidence (RWE) for payor negotiations and market positioning, the question arises: How can sponsors effectively advocate for their utilization to address the needs of a drug development program?